Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Comparison of the Serum Metabolic Fingerprint of Different Exercise Modes in Men with and without Metabolic Syndrome.

Siopi A, Deda O, Manou V, Kosmidis I, Komninou D, Raikos N, Theodoridis GA, Mougios V.

Metabolites. 2019 Jun 15;9(6). pii: E116. doi: 10.3390/metabo9060116.

2.

Association between lifestyle and anthropometric parameters and thyroid nodule features.

Panagiotou G, Komninou D, Anagnostis P, Linardos G, Karoglou E, Somali M, Duntas L, Kita M, Tziomalos K, Pazaitou-Panayiotou K.

Endocrine. 2017 Jun;56(3):560-567. doi: 10.1007/s12020-017-1285-6. Epub 2017 Apr 8.

PMID:
28390011
3.

Effects of Different Exercise Modes on the Urinary Metabolic Fingerprint of Men with and without Metabolic Syndrome.

Siopi A, Deda O, Manou V, Kellis S, Kosmidis I, Komninou D, Raikos N, Christoulas K, Theodoridis GA, Mougios V.

Metabolites. 2017 Jan 26;7(1). pii: E5. doi: 10.3390/metabo7010005.

4.

Changes in Thyroid Hormone Levels Within the Normal and/or Subclinical Hyper- or Hypothyroid Range Do Not Affect Circulating Irisin Levels in Humans.

Panagiotou G, Pazaitou-Panayiotou K, Paschou SA, Komninou D, Kalogeris N, Vryonidou A, Mantzoros CS.

Thyroid. 2016 Aug;26(8):1039-45. doi: 10.1089/thy.2016.0098.

PMID:
27267080
5.

The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.

Bartels LE, Mattheolabakis G, Vaeth BM, LaComb JF, Wang R, Zhi J, Komninou D, Rigas B, Mackenzie GG.

Carcinogenesis. 2016 Apr;37(4):420-429. doi: 10.1093/carcin/bgw017. Epub 2016 Feb 10.

6.

Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.

Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, Rigas B.

Breast Cancer Res. 2012 Jan 31;14(1):R20.

7.

Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, Rigas B.

Cancer Res. 2011 Dec 15;71(24):7617-27. doi: 10.1158/0008-5472.CAN-11-2349. Epub 2011 Oct 24.

8.

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B.

Cancer Prev Res (Phila). 2011 Jul;4(7):1052-60. doi: 10.1158/1940-6207.CAPR-11-0067. Epub 2011 Apr 4.

9.

Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.

Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, Rigas B.

J Pharmacol Exp Ther. 2011 Jun;337(3):876-86. doi: 10.1124/jpet.111.180224. Epub 2011 Mar 21.

10.

The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.

Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, Rigas B.

Br J Pharmacol. 2011 Apr;162(7):1521-33. doi: 10.1111/j.1476-5381.2010.01162.x.

11.

Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.

Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, Komninou D, Rigas B.

Carcinogenesis. 2010 Nov;31(11):1982-90. doi: 10.1093/carcin/bgq149. Epub 2010 Jul 12.

12.

Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.

Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, Rigas B.

Gastroenterology. 2010 Oct;139(4):1320-32. doi: 10.1053/j.gastro.2010.06.044. Epub 2010 Jun 20. Erratum in: Gastroenterology. 2012 Mar;142(3):676.

13.

Induction of colon tumorigenesis by glutathione depletion in p53-knock-out mice.

Richie JP Jr, Komninou D, Albino AP.

Int J Oncol. 2007 Jun;30(6):1539-43.

PMID:
17487376
14.

Enhanced levels of glutathione and protein glutathiolation in rat tongue epithelium during 4-NQO-induced carcinogenesis.

Huang Z, Komninou D, Kleinman W, Pinto JT, Gilhooly EM, Calcagnotto A, Richie JP Jr.

Int J Cancer. 2007 Apr 1;120(7):1396-401.

15.

Methionine restriction inhibits colon carcinogenesis.

Komninou D, Leutzinger Y, Reddy BS, Richie JP Jr.

Nutr Cancer. 2006;54(2):202-8.

PMID:
16898864
16.

Glutathione depletion enhances the formation of endogenous cyclic DNA adducts derived from t-4-hydroxy-2-nonenal in rat liver.

Chung FL, Komninou D, Zhang L, Nath R, Pan J, Amin S, Richie J.

Chem Res Toxicol. 2005 Jan;18(1):24-7.

PMID:
15651845
17.

Tissue glutathione and cysteine levels in methionine-restricted rats.

Richie JP Jr, Komninou D, Leutzinger Y, Kleinman W, Orentreich N, Malloy V, Zimmerman JA.

Nutrition. 2004 Sep;20(9):800-5.

PMID:
15325691
18.

Obesity, adipocytokines, and insulin resistance in breast cancer.

Rose DP, Komninou D, Stephenson GD.

Obes Rev. 2004 Aug;5(3):153-65. Review.

PMID:
15245384
19.

Insulin resistance and its contribution to colon carcinogenesis.

Komninou D, Ayonote A, Richie JP Jr, Rigas B.

Exp Biol Med (Maywood). 2003 Apr;228(4):396-405. Review.

PMID:
12671184
20.

Protein glutathiolation in human blood.

Kleinman WA, Komninou D, Leutzinger Y, Colosimo S, Cox J, Lang CA, Richie JP Jr.

Biochem Pharmacol. 2003 Mar 1;65(5):741-6.

PMID:
12628487
21.

Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study.

El-Bayoumy K, Richie JP Jr, Boyiri T, Komninou D, Prokopczyk B, Trushin N, Kleinman W, Cox J, Pittman B, Colosimo S.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1459-65.

Supplemental Content

Loading ...
Support Center